FLSM
PBLS

Frazier Life Sciences Management’s Parabilis Medicines Inc PBLS Stock Holding History

Frazier Life Sciences Management’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.6M Buy
+1,920,805
New +$53.1M 1.14% 17

Other funds holding PBLS

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Frazier Life Sciences Management's PBLS Position: Q2 2026 in Review

Frazier Life Sciences Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 1,920,805 shares worth $52.6M. The stake represents 1.14% of the portfolio and ranks #17 among its holdings.

63 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Frazier Life Sciences Management held 1,920,805 shares of Parabilis Medicines Inc worth $52.6M as of Q2 2026.
  • Parabilis Medicines Inc was a new Frazier Life Sciences Management position in Q2 2026.
  • Parabilis Medicines Inc made up 1.14% of Frazier Life Sciences Management's portfolio in Q2 2026, its #17 holding.
  • 63 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.